Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA is rolling out a new pilot program to accelerate the path from drug discovery to human clinical trials. Part of the Trump administration's Operation TrialBlazer, the initiative pairs drug companies with research institutions for rolling application reviews. The goal: close the gap with China, where early-stage drug development is faster and cheaper.
The FDA is launching a pilot program designed to speed up early-stage drug development — a space where the U.S. has been losing ground to China. Under the initiative, drug companies will be paired with qualified research institutions to help prepare and submit new drug applications, with the FDA reviewing components on a rolling basis rather than waiting for a complete submission before starting its review.
The program is part of Operation TrialBlazer, the Trump administration's broader push to restore American leadership in clinical trials. FDA officials say the rolling review approach will "create certainty and reduce unnecessary delays." Up to 10 sponsor-institution pairings will be selected for the pilot, and lessons learned could eventually inform a formal accreditation model for research institutions.
By the Numbers:
Why it matters: Early-stage drug development in China is both cheaper and faster, giving it a growing edge in the global biotech race. This pilot is a concrete — if limited — step toward modernizing the U.S. drug development pipeline, with implications for how quickly new therapies can reach patients.
